Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat

Huang,Hui-Qiong; Tang,Jing; Zhou,Sheng-Tao; Yi,Tao; Peng,Hong-Ling; Shen,Guo-Bo; Xie,Na; Huang,Kai; Yang,Tao; Wu,Jin-Hua; Huang,Can-Hua; Wei,Yu-Quan; Zhao,Xia

doi:10.3892/ijo.2012.1465

Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat

Authors:
- Hui-Qiong Huang
- Jing Tang
- Sheng-Tao Zhou
- Tao Yi
- Hong-Ling Peng
- Guo-Bo Shen
- Na Xie
- Kai Huang
- Tao Yang
- Jin-Hua Wu
- Can-Hua Huang
- Yu-Quan Wei
- Xia Zhao
View Affiliations

Affiliations: Gynecological Oncology of Biotherapy Laboratory, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, P.R. China, Gynecological Oncology of Biotherapy Laboratory, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, P.R. China, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China
Published online on: May 8, 2012 https://doi.org/10.3892/ijo.2012.1465
Pages: 523-532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Orlistat is an orally administered anti-obesity drug that has shown significant antitumor activity in a variety of tumor cells. To identify the proteins involved in its antitumor activity, we employed a proteomic approach to reveal protein expression changes in the human ovarian cancer cell line SKOV3, following Orlistat treatment. Protein expression profiles were analyzed by 2-dimensional polyacrylamide gel electrophoresis (2-DE) and protein identification was performed on a MALDI-Q-TOF MS/MS instrument. More than 110 differentially expressed proteins were visualized by 2-DE and Coomassie brilliant blue staining. Furthermore, 71 proteins differentially expressed proteins were positively identified via mass spectrometry (MS)/MS analysis. In particular, PKM1/2, a key enzyme involved in tumorigenesis, was found to be significantly downregulated in SKOV3 cells following treatment with Orlistat. Moreover, PKM1/2 was proved to be downregulated in SKOV3 cells by western blot analysis after treatment with Orlistat. Taken together, using proteomic tools, we identified several differentially expressed proteins that underwent Orlistat-induced apoptosis, particularly PKM2. These changes confirmed our hypothesis that Orlistat is a potential inhibitor of ovarian cancer and can be used as a novel adjuvant antitumor agent.

View Figures

View References

1	Clemens MJ: Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene. 23:3180–3188. 2004. View Article : Google Scholar : PubMed/NCBI
2	Bull JH, Ellison G, Patel A, et al: Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer. 84:1512–1519. 2001. View Article : Google Scholar : PubMed/NCBI
3	Rashid A, Pizer ES, Moga M, et al: Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol. 150:201–208. 1997.PubMed/NCBI
4	Gansler TS, Hardman W III, Hunt DA, et al: Increased expression of fatty acid synthase (OA-159) in ovarian neoplasms predicts shorter survival. Hum Pathol. 18:686–692. 1997. View Article : Google Scholar : PubMed/NCBI
5	Gansler TS, Hardman W III, Hunt DA, et al: Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res. 23:335–339. 2003.PubMed/NCBI
6	Nemoto T, Terashima S, Kogure M, et al: Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma. Pathobiology. 69:297–303. 2001. View Article : Google Scholar : PubMed/NCBI
7	Kusakabe T, Nashimoto A, Honma K and Suzuki T: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology. 40:71–79. 2002. View Article : Google Scholar : PubMed/NCBI
8	Piyathilake CJ, Frost AR, Manne U, et al: The expression of fatty acid synthase (FAS) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol. 31:1068–1073. 2000. View Article : Google Scholar : PubMed/NCBI
9	Pizer ES, Lax SF, Kuhajda FP, Pasternack GR and Kurman RJ: Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer. 83:528–537. 1998. View Article : Google Scholar : PubMed/NCBI
10	Alò PL, Visca P, Marci A, Mangoni A, Botti C and Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 77:474–482. 1996.PubMed/NCBI
11	Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR and Kuhajda FP: Inhibition of fatty acid synthase delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56:189–193. 1996.PubMed/NCBI
12	Alò PL, Visca P, Botti C, et al: Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/ atypical hyperplastic or normal breast tissue. Am J Clin Pathol. 116:129–134. 2001.PubMed/NCBI
13	Alò PL, Visca P, Framarino ML, et al: Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep. 7:1383–1388. 2000.PubMed/NCBI
14	Costello LC and Franklin RB: ‘Why do tumour cells glycolyse?’: from glycolysis through citrate to lipogenesis. Mol Cell Biochem. 280:1–8. 2005.
15	De Schrijver E, Brusselmans K, Heyns W, Verhoeven G and Swinnen JV: RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 63:3799–3804. 2003.PubMed/NCBI
16	Menendez JA, Vellon L and Lupu R: Orlistat: From antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med (Maywood). 230:151–154. 2005.PubMed/NCBI
17	Pemble CW IV, Johnson LC, Kridel SJ and Lowther WT: Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 14:704–709. 2007. View Article : Google Scholar : PubMed/NCBI
18	Knowles LM, Axelrod F, Browne CD and Smith JW: A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem. 279:30540–30545. 2004. View Article : Google Scholar : PubMed/NCBI
19	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin. 58:71–96. 2008.
20	Raki M, Rein DT, Kanerva A and Hemminki A: Gene transfer approaches for gynecological diseases. Mol Ther. 14:154–163. 2006. View Article : Google Scholar : PubMed/NCBI
21	Liu R, Li Z, Bai S, et al: Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics. 8:70–85. 2009. View Article : Google Scholar
22	Tong A, Wu L, Lin Q, et al: Proteomics analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics. 8:2012–2023. 2008. View Article : Google Scholar : PubMed/NCBI
23	Liu R, Wang K, Yuan K, et al: Integrative oncoproteomics strategies for anticancer drug discovery. Expert Rev Proteomics. 7:411–429. 2009. View Article : Google Scholar : PubMed/NCBI
24	Medes G, Thomas A and Weinhouse S: Metabolism of neoplastic tissue. IV: A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13:27–29. 1953.PubMed/NCBI
25	Witkowski A, Joshi AK and Smith S: Coupling of the de novo fatty acid biosynthesis and lipoylation pathways in mammalian mitochondria. J Biol Chem. 282:14178–14185. 2007. View Article : Google Scholar : PubMed/NCBI
26	Chirala SS and Wakil SJ: Structure and function of animal fatty acid synthase. Lipids. 39:1045–1053. 2004. View Article : Google Scholar : PubMed/NCBI
27	Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD and Pasternack GR: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 91:6379–6383. 1994. View Article : Google Scholar : PubMed/NCBI
28	Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
29	Guminska M, Ignacak J, Kedryna T and Stachurska MB: Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. Acta Biochim Pol. 44:711–724. 1997.PubMed/NCBI
30	Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 15:300–308. 2005. View Article : Google Scholar : PubMed/NCBI
31	Dombrauckas JD, Santarsiero BD and Mesecar AD: Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry. 44:9417–9429. 2005. View Article : Google Scholar : PubMed/NCBI
32	Spoden GA, Mazurek S, Morandell D, et al: Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer. 123:312–321. 2008. View Article : Google Scholar : PubMed/NCBI
33	Steták A, Veress R, Ovádi J, Csermely P, Kéri G and Ullrich A: Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 67:1602–1608. 2007.PubMed/NCBI
34	Janke J, Schlüter K, Jandrig B, et al: Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med. 191:1675–1686. 2000. View Article : Google Scholar : PubMed/NCBI
35	Wu N, Zhang W, Yang Y, et al: Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics. 6:6095–6106. 2006. View Article : Google Scholar : PubMed/NCBI